BeiGene has a strong presence at this year’s AACR, which features several notable duels.

Projects from the likes of BioNTech, Transgene and Scancell will feature, but still have much to prove.

After beating Darzalex, GSK’s withdrawn anti-BCMA ADC beats Velcade in early multiple myeloma.

The 2024 AACR abstract title drop features several noteworthy clinical studies.

The company reckons its tech could solve problems with current ADCs, but the market isn’t giving it much credit yet.